Dan Tardiff
Chief Scientific Officer CAMP4 Therapeutics
Dan Tardiff, PhD, is Chief Scientific Officer of CAMP4 where he oversees Platform and Discovery Teams to expand the scope of CAMP4’s discovery platform and advance the pipeline towards the clinic.
Prior to joining CAMP4, Dr. Tardiff led drug discovery projects and teams in both small biotech and large pharma across multiple drug modalities. Dr. Tardiff most recently led a team in the Rare Disease Research Unit at Pfizer exploring genetic medicines for rare neurological disorders. Prior to Pfizer, Dr. Tardiff was a scientific co-founder of Yumanity Therapeutics, where he helped build a platform to discover novel therapeutics for the treatment of neurodegenerative diseases. At Yumanity, he led teams from screening through translational research to discover new therapeutic targets and drug candidates, including a clinical-stage small molecule targeting stearoyl-CoA desaturase for the potential treatment of Parkinson’s disease.
Dr. Tardiff earned his BS in Biochemistry from Stonehill College and his PhD from Brandeis University. He completed his post-doctoral training at the Whitehead Institute for Biomedical Research with Dr. Susan Lindquist
Seminars
- SYNGAP is a synaptic protein that when mutated results in haploinsufficiency characterized by developmental delays, behavioral issues, limited communication, and epilepsy
- CMP-002 is an antisense oligonucleotide that targets a noncoding regulatory RNA to increase SYNGAP1 transcription, which ameliorates multiple phenotypes in a mouse model and increases SYNGAP protein in monkeys when administered by intrathecal injection
- Preparation is underway to enable the assessment of CMP-002 in a global Phase 1/2 clinical study in SYNGAP1-related disorder patient
